Torrid Holdings Inc. (CURV)

Blueprint Medicines Stock Forecast

Stock Price Forecast

The 3 analysts that cover Blueprint Medicines stock have a consensus rating of "Hold" and an average price target of $5.00, which forecasts a 100.00% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $6.00.

Price Target: $5.00 (+100.00%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$4.00	$5.00	$5.00	$6.00
Change	+60.00%	+100.00%	+100.00%	+140.00%

* Price targets were last updated on Jun 6, 2025.

Analyst Ratings

The average analyst rating for Blueprint Medicines stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	0	0	0	0	0	0
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	2
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Dana Telsey Telsey Advisory Group	Telsey Advisory Group	Hold Maintains $6	Hold	Maintains	$6	+140.00%	Jun 6, 2025
Dana Telsey Telsey Advisory Group	Telsey Advisory Group	Hold Maintains $6	Hold	Maintains	$6	+140.00%	Jun 2, 2025
Brooke Roach Goldman Sachs	Goldman Sachs	Hold Maintains $4.5 → $5	Hold	Maintains	$4.5 → $5	+100.00%	Mar 21, 2025
Dana Telsey Telsey Advisory Group	Telsey Advisory Group	Hold Maintains $5 → $6	Hold	Maintains	$5 → $6	+140.00%	Mar 21, 2025
Dana Telsey Telsey Advisory Group	Telsey Advisory Group	Hold Maintains $5	Hold	Maintains	$5	+100.00%	Mar 14, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.06B

Decreased by -4.23%

from 1.10B

Revenue Next Year

1.04B

Decreased by -1.89%

from 1.06B

EPS This Year

0.13

Decreased by -13.54%

from 0.15

EPS Next Year

0.19

Increased by 48.13%

from 0.13

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Jan 30, 2021	Jan 29, 2022	Jan 28, 2023	Feb 3, 2024	Feb 1, 2025	Feb 1, 2026	Feb 1, 2027	Feb 1, 2028
Revenue	984.17M	1.30B	1.29B	1.15B	1.10B	1.06B	1.04B	1.04B
Revenue Growth	-5.09%	31.81%	-0.70%	-10.57%	-4.19%	-4.23%	-1.89%	0.58%
EPS	0.22	-0.27	0.48	0.11	0.15	0.13	0.19	0.22
EPS Growth	-42.20%	-	-	-77.08%	36.36%	-13.54%	48.13%	16.82%
Forward PE	-	-	-	-	-	19.28	13.01	11.14
No. Analysts	-	-	-	-	-	9	8	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028
High	1.1B	1.1B	1.1B
Avg	1.1B	1.0B	1.0B
Low	988.8M	976.3M	988.1M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-0.3%	3.9%	5.0%
Avg	-4.2%	-1.9%	0.6%
Low	-10.4%	-7.6%	-4.7%

EPS Forecast

EPS	2026	2027	2028
High	0.19	0.26	0.30
Avg	0.13	0.19	0.22
Low	0.09	0.13	0.15

EPS Growth

EPS Growth	2026	2027	2028
High	26.0%	102.4%	58.5%
Avg	-13.5%	48.1%	16.8%
Low	-41.2%	-1.8%	-23.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.